Jylamvo®

Methotrexate oral solution

Methotrexate oral solution

For use in rheumatological, dermatological and oncological diseases.

Jylamvo was granted European Union Centralised Licence in 2017, and followingly obtained marketing authorisations in Great Britain, Switzerland, Kuwait, UAE and Saudi Arabia.

The product received FDA approval in 2022 and was divested to Shorla Oncology in 2023.

The marketing authorisations for the EU and GB were transferred to Oresund Pharma in 2024.

Key partners

For enquiries related to Jylamvo in the US, please contact Shorla Oncology:

For enquiries related to Jylamvo in any other territories (non-US), please contact Oresund Pharma:

  • To ensure the medicine is used correctly and to avoid medication errors, Educational Materials are provided to all healthcare professionals who may potentially prescribe or dispense Jylamvo in Europe and GB. The Educational Package has been reviewed and approved by the relevant national regulatory authority for distribution in that particular market.

    The educational package comprises the following documents:

    • Guide for healthcare professionals – prescribing physician and dispensing pharmacist.

    • The Summary of Product Characteristics (SmPC).

    • The Package Leaflet (PL).

    • Patient Card.

    By clicking on these links, you confirm that you are a healthcare professional.

    For information specific to GB, click here.

    If you are not a healthcare professional, click here to return to the home page.

  • For UK Medical Information enquiries regarding Jylamvo or should you wish to report a Product Complaint or Adverse Event, please use the following contact details:

    GB

    Telephone: +44 (0)330 1359 437

    Fax: +44 (0)190 8533 370

    Email: medinfo.uk@esteve.com